Predicting response to chemotherapy in rectal cancer
Ontology highlight
ABSTRACT: Neoadjuvant chemoradiotherapy (CRT) is used in locally advanced rectal cancer when tumours threaten the circumferential resection margin. A variable response to treatment remains, notwithstanding potentially significant morbidity, and no clinically routinely used predictive biomarkers guide decision making. This experimental study aimed to identify significantly differentially expressed proteins between patients responding or not to CRT, using novel temporal proteomic profiling, and to validate any proteins of interest.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Rectum, Rectum Smooth Muscle Tissue, Epithelial Cell, Epithelium Of Rectum, Fibroblast, Macrophage
DISEASE(S): Rectum Cancer
SUBMITTER:
Rosalind Jenkins
LAB HEAD: Rosalind Elspeth Jenkins
PROVIDER: PXD008436 | Pride | 2018-03-12
REPOSITORIES: Pride
ACCESS DATA